Free tool
FAERS Monitor: Rezvoglar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761215 or its brand name (Rezvoglar, Insulin Glargine-Aglr). Reports on generic versions are filed under their own applications.
Reports
77
Serious
13
17% of reports
Hospitalization
8
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased16
- accidental underdose13
- incorrect dose administered11
- product dose omission issue10
- drug ineffective7
- injection site haemorrhage6
- hypoacusis4
- visual impairment4
- condition aggravated3
- death3
- dyspnoea3
- inappropriate schedule of product administration3
- incorrect product administration duration3
- injection site bruising3
- injection site pain3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 11 |
| 2025 | 32 |
| 2026 | 30 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,082 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| accidental underdoseSignal | 13 | 246.9 | 150.4 | 2,942 |
| incorrect product administration durationSignal | 3 | 37.8 | 12.5 | 74 |
| hypoacusisSignal | 4 | 25.4 | 9.8 | 71 |
| blood glucose increasedSignal | 16 | 23.2 | 15.0 | 321 |
| injection site haemorrhageSignal | 6 | 20.5 | 9.5 | 93 |
| incorrect dose administeredSignal | 11 | 13.2 | 7.6 | 113 |
| injection site bruisingSignal | 3 | 10.3 | 3.4 | 17 |
| product dose omission issueSignal | 10 | 9.3 | 5.2 | 67 |
| visual impairmentSignal | 4 | 8.8 | 3.4 | 21 |
| inappropriate schedule of product administrationSignal | 3 | 4.5 | 1.5 | 5 |
| condition aggravated | 3 | 2.7 | 0.9 | 2 |
| injection site pain | 3 | 2.7 | 0.9 | 2 |
| drug ineffective | 7 | 1.5 | 0.7 | 1 |
| dyspnoea | 3 | 1.4 | 0.5 | 0 |
| death | 3 | 1.0 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.